RUMI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 2.987
EU - Europa 2.285
AS - Asia 1.378
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 7
OC - Oceania 5
SA - Sud America 2
Totale 6.675
Nazione #
US - Stati Uniti d'America 2.955
CN - Cina 1.360
IE - Irlanda 998
FI - Finlandia 321
UA - Ucraina 275
DE - Germania 190
IT - Italia 173
SE - Svezia 129
GB - Regno Unito 73
FR - Francia 37
CA - Canada 32
RO - Romania 24
BE - Belgio 22
AT - Austria 12
NL - Olanda 10
IN - India 9
RU - Federazione Russa 8
EU - Europa 7
MU - Mauritius 6
AU - Australia 5
CH - Svizzera 5
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PL - Polonia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AR - Argentina 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
MY - Malesia 1
QA - Qatar 1
SA - Arabia Saudita 1
SG - Singapore 1
TR - Turchia 1
TW - Taiwan 1
Totale 6.675
Città #
Dublin 997
Chandler 643
Jacksonville 423
Nanjing 392
Ashburn 276
Princeton 168
Nanchang 163
Lawrence 159
Beijing 139
Wilmington 121
Shenyang 116
Hebei 110
Changsha 106
Helsinki 103
Medford 101
New York 93
Jiaxing 91
Ann Arbor 79
Tianjin 61
Hangzhou 58
Boardman 47
Shanghai 46
Milan 34
Woodbridge 29
Norwalk 28
Toronto 28
Pavia 25
Brussels 22
Seattle 22
Timisoara 22
Washington 20
Fairfield 15
Jinan 13
Verona 12
Auburn Hills 10
Falls Church 9
Florence 9
Zhengzhou 9
Ningbo 7
Pune 7
Vienna 7
Des Moines 6
Guangzhou 6
Taizhou 6
Los Angeles 5
Monmouth Junction 5
Orange 5
Rome 5
Dearborn 4
Fuzhou 4
Gallarate 4
San Francisco 4
Brugherio 3
Canberra 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
Lugano 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Tappahannock 3
Andover 2
Antony 2
Borås 2
Chicago 2
Dronten 2
Falkenstein 2
Genoa 2
Gießen 2
Haikou 2
Kemerovo 2
Lanzhou 2
Leawood 2
Manchester 2
Monza 2
Paderno Dugnano 2
Paris 2
Seelze 2
Sofia 2
Srbica 2
The Bronx 2
Almere Stad 1
Amsterdam 1
Basel 1
Berlin 1
Bolgare 1
Boston 1
Bovisio Masciago 1
Cadoneghe 1
Cairo 1
Changchun 1
Chesterfield 1
Collegeville 1
Como 1
Cothen 1
Doha 1
Dundalk 1
Edmonton 1
Totale 4.964
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 90
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 80
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 76
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 75
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 74
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 73
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 72
Blast phase of essential thrombocythemia: A single center study. 71
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 70
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 69
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 69
An insidious presentation of splenic marginal zone lymphoma 67
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 66
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 66
JAK2 (V617F) mutation in healthy individuals 64
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 64
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 64
Peripheral intraneutrophil diplococci in a case of meningococcemia. 64
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 63
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 63
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 60
Clinical significance of somatic mutation in unexplained blood cytopenia 60
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 59
Cardiovascular events and intensity of treatment in polycythemia vera. 59
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 58
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 57
Familial chronic myeloproliferative disorders: the state of the art 57
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 57
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 57
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 56
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 56
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 56
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 56
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 55
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 55
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 55
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 55
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 54
Allelic imbalance in CALR somatic mutagenesis 54
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 54
Role of the molecular staging and response in the management of follicular lymphoma patients 53
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 53
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 53
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 52
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 52
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 51
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 51
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 50
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 50
Clinical relevance of JAK2 (V617F) mutant allele burden 50
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 50
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 49
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 49
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 48
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 48
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 47
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 47
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 47
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 47
Mutational status of myeloproliferative neoplasms. 46
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 46
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 46
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 46
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 46
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 46
Mutations and prognosis in primary myelofibrosis 45
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 45
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 45
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 45
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 45
Improving survival trends in primary myelofibrosis: an international study. 45
LNK mutations in familial myeloproliferative neoplasms. 45
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 44
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 44
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 43
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 43
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 43
Myelofibrotic transformation in essentialthrombocythemia. Author reply 42
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 42
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 42
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 42
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 42
Diagnosis and management of prefibrotic myelofibrosis. 42
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 41
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 40
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 40
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 40
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 40
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 39
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 39
Somatic mutations of calreticulin in myeloproliferative neoplasms 39
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 39
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 38
How I treat essential thrombocythemia. 38
Masked polycythemia vera diagnosed according to WHO and BCSH classification 38
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 36
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 36
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. 35
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 35
Totale 5.194
Categoria #
all - tutte 26.010
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.010


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201925 0 0 0 0 0 0 0 0 0 1 3 21
2019/20201.573 479 646 4 50 3 60 18 95 27 146 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022693 9 4 23 11 17 38 6 38 33 38 115 361
2022/20232.224 223 118 21 135 204 169 3 101 1.113 15 91 31
2023/2024945 123 171 57 85 100 302 27 66 10 4 0 0
Totale 7.016